Diagonal Therapeutics
Advancing clustering antibodies to correct disease at the root
- Headquarters
- Watertown, Massachusetts
- Employees
- 11–50
- Founded
- 2022
- Website
- diagonaltx.com
- Last Round
- Series BJan 2026
- Rounds
- 2
About
Diagonal Therapeutics pioneers a new class of clustering antibody medicines designed to correct the root causes of severe genetic and immune-mediated diseases. Founded in 2022, the company's lead program DIAG723 targets HHT by restoring ALK1 signaling and is advancing toward clinical trials in 2026.
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Jan 2026
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biopharmaceutical services company
Specialty pharmaceutical company
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.